These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38348277)

  • 1. Macrophage-Related Gene Signatures for Predicting Prognosis and Immunotherapy of Lung Adenocarcinoma by Machine Learning and Bioinformatics.
    Xiang Y; Wang G; Liu B; Zheng H; Liu Q; Ma G; Du J
    J Inflamm Res; 2024; 17():737-754. PubMed ID: 38348277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes.
    Hua L; Wu J; Ge J; Li X; You B; Wang W; Hu B
    Front Cell Dev Biol; 2023; 11():1060086. PubMed ID: 37234773
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
    Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
    Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
    Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
    Front Immunol; 2022; 13():960738. PubMed ID: 36032135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
    Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
    Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine Learning-Based Integration Develops a Macrophage-Related Index for Predicting Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
    Li Z; Guo M; Lin W; Huang P
    Arch Med Res; 2023 Nov; 54(7):102897. PubMed ID: 37865004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a three-gene expression signature and construction of a prognostic nomogram predicting overall survival in lung adenocarcinoma based on TCGA and GEO databases.
    Zhou Y; Gao S; Yang R; Du C; Wang Y; Wu Y
    Transl Lung Cancer Res; 2022 Jul; 11(7):1479-1496. PubMed ID: 35958325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An
    Han Y; Wong FC; Wang D; Kahlert C
    Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validating a Macrophage Marker Gene Signature (MMGS) in Lung Adenocarcinoma Prognosis and Response to Immunotherapy.
    Song P; Wusiman D; Li W; Guo L; Ying J; Gao S; He J
    J Immunother; 2023 Jul-Aug 01; 46(6):205-215. PubMed ID: 37220007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
    Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
    Front Genet; 2022; 13():1017866. PubMed ID: 36699466
    [No Abstract]   [Full Text] [Related]  

  • 14. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of a novel phagocytosis regulators-related signature with potential prognostic and immunotherapeutic value in patients with lung adenocarcinoma.
    Li J; Du Q; Sun J; Xiang L; Wang S
    Front Oncol; 2022; 12():988332. PubMed ID: 36408131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a prognostic signature for lung adenocarcinoma by integration of 7 pyroptosis-related genes and cross-validation between the TCGA and GEO cohorts: A comprehensive bioinformatics analysis.
    Zhang W; Wan S; Qu Z; Ge J; Zhang C; Li C; Jiang Y
    Medicine (Baltimore); 2022 Jul; 101(29):e29710. PubMed ID: 35866781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor microbiome derived glycolysis-lactate signatures depicts immune heterogeneity in lung adenocarcinoma by integration of microbiomic, transcriptomic, proteomic and single-cell data.
    Deng X; Chen X; Luo Y; Que J; Chen L
    Front Microbiol; 2023; 14():1202454. PubMed ID: 37664112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on TCGA and GEO databases.
    Zhao J; Guo C; Ma Z; Liu H; Yang C; Li S
    Lung Cancer; 2020 Nov; 149():90-96. PubMed ID: 33002836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
    Wang H; Lu X; Chen J
    BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.